Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

Fintel reports that on February 3, 2026, Piper Sandler downgraded their outlook for Vertex (NasdaqGM:VERX) from Overweight to Neutral. Analyst Price Forecast Suggests 55.68% Upside As of January 14, ...

Vertex Pharmaceuticals (NasdaqGS:VRTX) is reassessing its pain management program after disappointing FDA label discussions for Journavx. Phase II data for pain candidate VX-993 did not meet ...

Vertex Pharmaceuticals Incorporated remains a buy despite recent share price weakness, supported by its dominant cystic fibrosis franchise and robust late-stage pipeline. Alyftrek's launch extends ...

(NASDAQ:VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today released its 2025 End‑of‑Year U.S. Sales Tax Rates and Rules Report. Tracking 12,414 U.S. tax ...

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

In mid-January 2026, Bernstein upgraded Vertex Pharmaceuticals to Outperform and UBS initiated coverage with a Buy rating, ...

Vertex Pharmaceuticals’ breakthrough in cystic fibrosis was a medicine that treats just 4% of patients who have the lung disorder. Today, Vertex’s portfolio of blockbuster CF products spans multiple ...

Vertex Flooring Presents High-Performance SPC Flooring Designed for Stability, Style, and Durability HOLLISTON, MA, ...